EN.10

The EN.10 trial is a Phase II study that focuses on finding the best follow-up treatment after surgery for early-stage endometrial cancer. Specifically, the trial looks at cancers with certain genetic traits (Pole-mutated and p53-wildtype/NSMP). The main goal is to see how often cancer returns in the pelvic area over a three-year period when a reduced or customised post-surgery treatment is used.

After surgery to remove early-stage endometrial cancer, doctors often recommend additional treatments like radiotherapy or chemotherapy to lower the risk of the cancer coming back. However, some cancers have a very low chance of returning, and this study aims to find out if reducing or skipping these additional treatments is safe and can improve the patient’s quality of life.

In this trial, researchers will examine a sample of each participant’s cancer taken during surgery. Based on certain characteristics of the cancer, participants will be placed in one of three groups (sub-studies) to receive tailored treatment.

The purpose of this study is to identify women who may not need extra treatment or might need less treatment because their risk of the cancer returning is very low. About 120 people will participate in this project at hospitals across Australia and New Zealand, with around 325 participants worldwide.

The EN.10 trial is a collaboration between the Canadian Clinical Trials Group (CCTG) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG). The trial aims to improve patient outcomes and reduce the impact of this disease. It will be carried out at 10 sites in Australia, led by Professor Alison Brand AM, a Gynaecological Oncologist and the Director of ANZGOG.